Paper: IDH mutations sensitize cells to PARP inhibition

Researchers at Yale University School of Medicine are planning an NCI-sponsored clinical trial to test their hypothesis that cancer patients with isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations will have

Read the full 308 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE